Net Cash Provided by (Used in) Financing Activities in USD of Calidi Biotherapeutics, Inc. from Q2 2021 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Calidi Biotherapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and change rate from Q2 2021 to Q1 2025.
  • Calidi Biotherapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $8.11M, a 169% increase year-over-year.
  • Calidi Biotherapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $27.4M, a 5.78% decline from 2023.
  • Calidi Biotherapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $29M, a 140% increase from 2022.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Calidi Biotherapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $8.11M +$5.1M +169% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025
Q1 2024 $3.01M -$778K -20.5% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025
Q1 2023 $3.79M +$3.79M 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024
Q1 2022 $0 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023
Q2 2021 $214K 24 Mar 2021 30 Jun 2021 10-Q 10 Aug 2022

Calidi Biotherapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $27.4M -$1.68M -5.78% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025
2023 $29M +$17M +140% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025
2022 $12.1M 01 Jan 2022 31 Dec 2022 10-K 15 Mar 2024
* An asterisk sign (*) next to the value indicates that the value is likely invalid.